Canyon Labs, a provider of analytical and packaging lab testing and consulting for medical devices and pharmaceuticals, has entered a strategic acquisition with iuvo BioScience, a full-service provider of ophthalmic medical device and pharmaceutical clinical research services, that the companies claim will strengthen both their market positions. The agreement transfers iuvo's laboratory services and scientific consulting divisions to Canyon Labs, according to a company press release, enabling Canyon Labs to deliver comprehensive end-to-end solutions in pharmaceutical and medical device development while strengthening iuvo BioScience’s focus on ophthalmic clinical development contract research. The transition includes the full integration of iuvo's laboratory and consulting personnel into Canyon Labs’ operations; iuvo BioScience will retain its clinical research team and leadership structure.

Both companies are enabled to accelerate their specialized growth trajectories, according to the press release.

“By strategically aligning our organizations, we are delivering immediate value to our global client base through faster lead times, expanded capacities, and unparalleled expertise at every step of the process,” said Sarah Ptach, president of Canyon Labs. 

Ben Burton, president and CEO of iuvo BioScience, said, "This strategic decision reinforces our fundamental mission of accelerating patient access to breakthrough vision care treatments. By sharpening our focus on our ophthalmic clinical contract research business, we're strengthening our ability to provide the high touch, science-driven solutions our customers and partners have come to expect from iuvo."